Drug Profile


Alternative Names: CC-5013; CDC-501; CDC-5013; ENMD-0997; IMiD-3; Ladevina; Revimid™; Revlimid

Latest Information Update: 04 Jan 2017

Price : $50

At a glance

  • Originator Celgene Corporation
  • Developer Celgene Corporation; Dana-Farber Cancer Institute; H. Lee Moffitt Cancer Center and Research Institute; Indiana University School of Medicine; IRCCS San Raffaele; National Cancer Institute (USA); National Heart, Lung and Blood Institute; Roche; Roswell Park Cancer Institute; University of Florida; Washington University School of Medicine
  • Class 2 ring heterocyclic compounds; Antineoplastics; Imides; Isoindoles; Piperidones; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Immunomodulators; Interleukin 1 beta inhibitors; Interleukin 10 stimulants; Interleukin 2 receptor modulators; Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma; Myelodysplastic syndromes; Chronic lymphocytic leukaemia
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Multiple myeloma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Mantle-cell lymphoma; Multiple myeloma; Myelodysplastic syndromes
  • Phase III Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma; Prostate cancer
  • Phase II Acute myeloid leukaemia; Adult T-cell leukaemia-lymphoma; Histiocytosis; Hodgkin's disease
  • Phase I Cancer; Chronic myeloid leukaemia; Peripheral T-cell lymphoma
  • No development reported Eye neoplasms; Glioblastoma; Myelofibrosis
  • Discontinued Colorectal cancer; Heart failure; Hepatocellular carcinoma; Inflammation; Malignant melanoma

Most Recent Events

  • 13 Dec 2016 Phase-II clinical trials in Diffuse large B cell lymphoma (Combination therapy, First-line therapy, Late-stage disease) in Estonia (PO) (EudraCT2015-005173-20)
  • 06 Dec 2016 Efficacy data from the phase III StaMINA trial in Multiple myeloma (Maintenance therapy) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem-2016)
  • 06 Dec 2016 Efficacy and adverse events data from the phase III Myeloma XI trial in Multiple myeloma (Maintenance therapy, Newly-diagnosed) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top